Korro Bio Inc. has entered into an amended and restated employment agreement with Jeffrey Cerio, effective December 15, 2025. The new agreement increases Dr. Cerio's annual base salary to $425,000 and enhances severance terms, providing nine months of salary in the event of termination without cause or resignation for good reason, and 12 months of salary in similar circumstances within the change in control period. Dr. Cerio has also been awarded a $100,000 cash bonus, payable in two installments—half on December 31, 2025, and half on or about June 30, 2026—contingent on continued service. Additionally, he has been granted 41,902 restricted stock units, vesting in two equal tranches on June 15, 2026, and December 15, 2026, subject to continued service.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-324795), on December 18, 2025, and is solely responsible for the information contained therein.
Comments